In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK's Hal Barron On R&D Progress At Two-Year Mark

R&D Chief Says Doubters Are Coming Round

Executive Summary

Chief scientific officer at GSK, Hal Barron, talks about winning hearts and minds of 10,000 R&D employees, and adopting practices from acquired company Tesaro.

You may also be interested in...



New Front Opens in First-Line Ovarian Cancer Market: GSK’s Zejula Vs. AZ’s Lynparza

Two new PARP inhibitor studiesGSK’s PRIMA and AstraZeneca/Merck & Co.’s PAOLA-1  – are set to widen the ovarian cancer market after they reported highly positive first-line results in advanced patients at ESMO.

Horizon Sees Blockbuster Future For Tepezza After US Approval

Once a pariah because of its price gouging, the new approval represents a change of tack from Horizon.

Biopharma Leaders Join Trump And Thunberg In Davos

Often dismissed as a meeting of the global elite, Davos is nevertheless a chance for biopharma leaders to take part in ‘big picture’ debates

Topics

Related Companies

UsernamePublicRestriction

Register

IV124354

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel